溶栓治疗急性心肌梗死的疗效是明确的。通过溶栓方法,使导致心肌梗死的冠状动脉获得再灌流。早期再通灌流可以挽救缺血、受损的心肌,晚期再通灌流尽管不能挽救早期损伤的心肌,但能减少以后心律失常的发生,有助于心室功能的改善.促进侧支循环的灌流,加速心肌的愈合。应用肝素作为联合抗凝治疗是通过加速和增加血块溶解,阻止或延迟再闭塞来加强溶栓效果,其治疗原则就是加快溶栓速度,增加再通率并维持最初成功的再通,冠脉溶栓的全部临床效果取决于再通的速率及维持的时间。目前临床上常用的第一代溶栓剂有尿激酶,第二代有 t—PA 和单链尿激酶纤溶酶原激活物。此外,新型的溶栓剂尚有 Duteplase Thrombolytic therapy of acute myocardial infarction is clear. Coronary artery leading to myocardial infarction was reperfused by thrombolysis. Early recanalization can save the ischemic and damaged myocardium, and late recanalization can reduce the incidence of arrhythmia and improve ventricular function, although it can not save the early injured myocardium.It can promote the perfusion of collateral circulation, Accelerate myocardial healing. The use of heparin as a combined anticoagulant therapy enhances thrombolysis by accelerating and increasing clot lysis, stopping or delaying reocclusion. The principle of treatment is to speed up thrombolysis, increase the recanalization rate and maintain initial successful recanalization The complete clinical effect of the suppository depends on the rate of recanalization and the time of maintenance. The first generation of commonly used clinical thrombolytic agent urokinase, the second generation of t-PA and single-chain urokinase plasminogen activator. In addition, the new thrombolytic agent is Duteplase